A pregnant client is instructed to avoid cleaning a cat litter box. What condition is the nurse trying to prevent?

Dysmenorrhea is characterized by painful uterine contractions mediated by excessive prostaglandin F2-alpha release from the secretory endometrium. This biochemical surge causes myometrial hypercontractility and transient uterine ischemia, resulting in sharp pelvic pain and systemic symptoms. Elevated prostaglandins also stimulate gastrointestinal smooth muscle, leading to nausea and diarrhea.

A. Fibroids: Uterine leiomyomas are benign smooth muscle tumors that typically present with heavy menstrual bleeding or pelvic pressure. While they can cause secondary dysmenorrhea, they are primarily associated with menorrhagia and uterine enlargement. They do not typically cause the cyclic nausea and fatigue characteristic of primary dysmenorrhea.

B. PCOS: Polycystic ovary syndrome involves hormonal imbalances, including hyperandrogenism and anovulation, often leading to irregular periods rather than painful ones. Many patients with PCOS experience amenorrhea or oligomenorrhea. It is a metabolic and endocrine disorder rather than a condition defined by acute cyclic pain.

C. Amenorrhea: This term refers to the total absence of menstruation for 3 to 6 months or more. It is the physiological opposite of the symptoms described, as the client is actively experiencing a menstrual cycle. Amenorrhea can be caused by pregnancy, stress, or pituitary gland dysfunction.

D. Dysmenorrhea: The combination of severe cramping, nausea, and fatigue synchronized with the menstrual cycle is the classic presentation of primary dysmenorrhea. It occurs in the absence of pelvic pathology and usually begins shortly after menarche. Management involves prostaglandin synthetase inhibitors like ibuprofen to reduce uterine hyperactivity.

The management of preeclampsia at a pre-viable or early preterm gestation focuses on expectant management to allow for fetal growth. This involves close monitoring for maternal end-organ damage while maximizing the time the fetus remains in utero. The strategy balances maternal safety against the risks of neonatal prematurity.

A. Stop fetal growth: Preeclampsia often causes placental insufficiency, which may lead to intrauterine growth restriction (IUGR). However, the goal of medical care is to optimize perfusion and support growth, not to stop it. Fetal biophysical profiles are used to monitor growth.

B. Prolong pregnancy safely: At 28 weeks, the neonate faces significant morbidity from prematurity. Clinicians attempt to maintain the pregnancy to reach a more mature gestational age while blood pressure is controlled. Stabilization prevents acute maternal complications while the fetus gains weight.

C. Immediate delivery: Delivery is the only definitive cure for preeclampsia, but at 28 weeks, it is reserved only for "severe features" that are life-threatening. If the mother and fetus are stable, immediate delivery is avoided to prevent extreme neonatal complications. Delay allows for steroid administration.

D. Eliminate BP monitoring: Frequent blood pressure assessment is the most critical component of managing preeclampsia. Monitoring detects hypertensive crises and guides the administration of antihypertensive medications like labetalol. Eliminating this would lead to unmonitored vasospasm and stroke risk.